vTv Therapeutics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VTVT | NBP | TVGN | VOGX | VYGR | ABVC | |
|---|---|---|---|---|---|---|
| Market cap | 95.01M | 117.16M | 95.87M | 293.09M | 115.23M | 26.69M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -5.5 | -0.8 | — | — | -1.5 | -2.3 |
| Price/book | 3.8 | 0.6 | -1.4 | -58.4 | 0.7 | 2.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −5.65% | −75.89% | −75.61% | +51.77% | −55.69% | −64.79% |
| Today | +2.04% | 0.00% | −3.38% | −3.90% | +2.19% | +1.51% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All VTVT news ›vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Has Consensus Price Target of $55.83
View Our Latest Stock Report on vTv Therapeutics Shares of NASDAQ:VTVT opened at $25.17 on Friday. vTv Therapeutics has a 52-week low of $20.04 and a 52-week high of $44.00. The firm has a fifty day moving average of $30.28 and a 200 day…
Viridian Therapeutics (VRDN) Set to Announce Quarterly Earnings on Wednesday
Posted by Danessa Lincoln on Oct 28th, 2026 NASDAQ:VRDN opened at $24.09 on Wednesday. The business’s 50-day moving average is $21.65 and its two-hundred day moving average is $22.05. The firm has a market capitalization of $2.73 billion,…
vTv Therapeutics (NASDAQ:VTVT) Stock Rating Lowered by Wall Street Zen
Posted by Danessa Lincoln on Oct 26th, 2026 vTv Therapeutics (NASDAQ:VTVT – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen…
VC-H1: Where Beauty Blooms
PDF file | Product Brochure | Promotional Content Discover VC-H1 Botanic Collagen Peptides, a plant-based collagen alternative sourced from organic hibiscus. Clinically studied at just 1.5 g daily, VC-H1 supports natural collagen…
New Publication: A Roadmap for Disease-Modifying Therapies for T1D
The manuscript, titled “Clinical Trial Design Considerations for the Development of Disease-Modifying Therapies for Type 1 Diabetes,” was published in October 2026 in Diabetes. The authors included expert collaborators in addition to…
vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program - Slideshow
2026-10-21. The following slide deck was published by vTv Therapeutics Inc. The following slide deck was published by vTv Therapeutics Inc. in conjunction with this event.
vTv Therapeutics Highlights Cadisegliatin's Phase III Push to Tackle Type 1 Hypoglycemia
vTv Therapeutics (NASDAQ:VTVT) used a virtual key opinion leader event to outline the continuing burden of hypoglycemia in type 1 diabetes, present patient and physician market-research findings, and review the development program for its…
vTv Therapeutics Inc. - Class A Common Stock (VTVT)
Stock Price, News, Quote & History FinancialContent vTv Therapeutics Inc. - Class A Common Stock (VTVT) About vTv Therapeutics Inc. - Class A Common Stock (VTVT) VTV Therapeutics is a clinical-stage biopharmaceutical company focused on…
VSTM Stock Draws Bulls As Oncology Data And Targets Rise
Verastem Inc. stocks have been trading up by 12.08 percent after positive trial news boosted optimism for its cancer pipeline. VSTM is acting like a classic biotech battleground name. The story has real revenue now, but the company is…
vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
The Manila Times vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 New research spotlights hypoglycemia-related burdens in adults with type 1 diabe
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net3
- marketbeat.com2
- themarketsdaily.com2
- defenseworld.net1
- financialcontent.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.